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ORIGINAL ARTICLE
From the beginning of the human immunodefi-
ciency virus (HIV) epidemic in Taiwan in 1986,
the Taiwanese government decided to ensure that
all HIV-infected citizens had free access to anti-
retroviral therapy.1 The introduction of highly
active antiretroviral therapy (HAART) in April
1997 dramatically improved the survival of pa-
tients with HIV infection.1–3 These antiretroviral
agents, however, are expensive and must be used
in combination.4–6 The wholesale prices in the
United States ranged from approximately US$2500
per patient per year for the nucleoside analogs to
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Background/Purpose: Since the late 1980s, the Taiwanese government has provided all HIV-infected citi-
zens with free access to antiretroviral therapy. Recently, there is controversy as to whether or not free access
to expensive highly active antiretroviral therapy (HAART) should be continued for HIV-infected patients.
This study aimed to evaluate the cost-effectiveness of HAART therapy.
Methods: HAART-associated improvement in survival was obtained by analyzing the follow-up data of all
HIV-positive patients identified during April 1984 to March 1997 (pre-HAART era) and May 1997 to April
2003 (HAART era) in Taiwan. Data on quality of life in HIV-positive patients was obtained from a cross-
sectional survey of 224 patients using standard gamble method and World Health Organization Quality
of Life-BREF instrument. Information regarding the cost of HAART was obtained from the National
Health Insurance (NHI).
Results: In 2000, the average annual NHI expenditure on HAART per HIV-positive patient receiving
HAART was NT$210,018 (US$6177, at an exchange rate of 34.0 NT$/US$). In the AIDS group, the cost was
NT$176,441 (US$5189) per life year gained and NT$241,700 (US$7109) per quality-adjusted life year gained.
For non-AIDS patients, the corresponding costs were NT$226,156 (US$6652) and NT$332,582 (US$9782),
respectively. These estimates have not yet included the additional cost savings from HAART-associated re-
duction in hospitalization and use of antimicrobial agents for opportunistic infections, and the additional
life years gained from the reduction in HIV transmission under the universal availability of HAART.
Conclusion: HAART for HIV infection is cost-effective, especially when the societal and epidemiologic
factors are considered. We recommend that the policy of providing free HAART to all HIV-infected citizens
be continued. [J Formos Med Assoc 2007;106(8):631–640]
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US$8000 per patient per year for one of the pro-
tease inhibitors in 1998.7,8 Furthermore, the com-
bination therapy must be continued throughout
the patient’s life.4–6
In Taiwan, when the number of HIV-infected
patients was small, the National Health Insurance
(NHI) could cover the cost and provide all HIV-
infected citizens with free access to such therapy.1
Since 2003, however, a new wave of HIV epi-
demic of CRF07_BC subtype was introduced from
southwest China via heroin-trafficking routes into
Taiwan.9 Up till the end of 2006, at least 5034 in-
travenous heroin abusers have already been in-
fected.10 With the anticipated huge financial
burden on the NHI due to the explosive growth
in the number of new HIV cases, controversy has
emerged with regard to whether the policy of
providing free HAART should be continued.
Several studies have suggested that HAART is
cost-effective,8,11–13 with the incremental cost per
life year (LY) gained estimated at US$12,000–
21,000 in the United States,8 US$22,110 in
Swizerland,11 US$12,813–14,587 in Canada,12
and US$675–1622 in South Africa.13 These stud-
ies, nevertheless, were either based on hypothetical
computer simulations8,11 or on databases from
only a few hospitals.12,13 The present study aimed
to evaluate the cost-effectiveness of HAART in
HIV-infected patients through analyzing nation-
wide databases in Taiwan.
Methods
Study design
This was an intervention study comparing treat-
ment effectiveness before versus after the intro-
duction of HAART in Taiwan in April 1997. We
calculated the incremental cost-effectiveness ratio14
based on the average cost and the quality-adjusted
life expectancy (estimated mean quality-adjusted
lifetime survival) after the diagnosis of HIV in-
fection. Comparisons were made between the pre-
HAART era (April 1, 1984 to March 31, 1997) (as
the baseline scenario) and the HAART era (May 1,
1997 to April 30, 2003).
Survival data of HIV-infected patients
Both HIV infection and acquired immunodefi-
ciency syndrome (AIDS) are reportable diseases in
Taiwan.15 All identified cases must be confirmed
by Western blot and reported to the Centers for
Disease Control (Taipei, Taiwan). For each case
confirmed by Western blot, the Centers for Disease
Control maintains a periodically updated data
profile, including the date of diagnosis, age, gen-
der, date of development of AIDS,3 and date of
death. The survival status of each patient is fur-
ther verified by cross-checking with the national
death certification database maintained by the
Department of Health and Ministry of the Interior,
Taiwan.16
Survival analysis and extrapolation
The follow-up data were analyzed by the Kaplan–
Meier method17 to yield the estimated survival
function of HIV-infected patients in the two eras.
A constant excess hazard model was used to pro-
ject long-term survival of HIV-infected patients,
with linear extrapolation of a logit-transformed
curve of survival ratio between HIV-infected pa-
tients and an age- and gender-matched reference
population.3 The survival function of this refer-
ence population was generated by a Monte Carlo
method18 from the life table of the general popu-
lation of Taiwan. At the end of 2006, Taiwan had
a population of 22,876,527, of whom 16,443,867
(71.2%) were aged 15–64 years, and a life expec-
tancy at birth of 77.5 years. The statistics and life
tables for the general population were obtained
from vital statistics published by the Department
of Statistics, Ministry of the Interior, Executive
Yuan, Taiwan (available online at http://www.moi.
gov.tw/W3/stat/). The methodologic details have
been described elsewhere.3,18–22 To facilitate the
computation, we developed a software program
MC-QAS, which was built in the R and S-PLUS
2000 (MathSoft Inc., Cambridge, MA, USA) en-
vironment; it can be freely downloaded from
http://www.stat.sinica.edu.tw/jshwang (released
in December 2004). The standard error of the
survival estimate was obtained using a bootstrap
method.23 Life expectancy was estimated by 
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extrapolating the survival curves to 50 years after
the diagnosis of HIV infection.3
Quality of life data
Quality of life data from HIV-positive patients
during the HAART era in Taiwan was obtained
from a cross-sectional survey of 224 patients in
2000–2001. Health profiles were measured using
the abbreviated version of the World Health
Organization Quality of Life Instrument (WHO-
QOL-BREF),24,25 and health utility was assessed
using standard gamble method.26 Part of the re-
sults using WHOQOL-BREF have been reviewed
and published.25 The domain scores were ex-
pressed as a percentage of the highest possible
scores. To analyze the temporal trend in the qual-
ity of life after the diagnosis of HIV infection, the
scores were plotted against the interval between
the diagnosis of HIV infection and the time of the
survey. The kernel type smoother with a band-
width of 0.1 was used to estimate the mean quality
of life over time. As there were no data on the
quality of life in HIV-infected patients in the pre-
HAART era in Taiwan, we used a conservative
best-case analysis and assumed it to be the same
as that of the HAART era.
Quality-adjusted survival
Quality-adjusted survival was defined by the in-
tegration of survival and quality of life using the
following formula:18,19
where E(QAS ⎡ xi) is the expected value of quality-
adjusted survival of patient population xi,
E(q (t ⎡ xi)) is the expected health utility of patient
population xi, S(t ⎡ xi) is the survival function of
patient population xi, and xi is the patient popu-
lation either during the pre-HAART era or the
HAART era.
The unit of E(QAS ⎡ xi) is the quality-adjusted
life year (QALY). The quality-adjusted life expec-
tancy (QALE) after the diagnosis of HIV infection
was calculated by the integration of life expectancy
and temporal trend of health utility.
Cost of antiretroviral therapy
The medication cost of HAART per patient per year
was calculated by dividing the total national ex-
penditure on HAART with the number of HAART
users in the year 2000. Because no data were avail-
able for the cost of antiretroviral therapy in the
pre-HAART era in Taiwan, we assumed that the cost
of single nucleotide reverse transcription inhibitor
(NRTI) therapy commonly used in the pre-HAART
era in Taiwan was 1/6 that of a HAART regimen
using 2 NRTIs +1 protease inhibitor, according to
the reported ratio of wholesale drug prices in the
United States (US$2500 per patient per year for
the nucleoside analogs; US$8000 per patient per
year for one of the protease inhibitors).7,8
Because the above-stated HAART cost data from
the NHI was cross-sectional, we reconstructed the
longitudinal average cumulative cost by the fol-
lowing method. The average medication cost per
patient in the nth year after the diagnosis was es-
timated by multiplying unit medication cost per
patient per year with the average of probabilities of
survival at the beginning and at the end of the nth
year. Since 2002, the practice of initiating HAART
in asymptomatic HIV-infected patients has changed
to the new criteria of CD4 count < 350/µL or peri-
pheral blood HIV-RNA level >55,000 copies/mL.4,5
We therefore assumed that, on average, no HAART
was needed in the first 2 years after diagnosis for
HIV-positive patients without initial presentation
of AIDS-defining illnesses.3 The cumulative cost
was adjusted by a 3% annual discount rate.
Incremental cost-effectiveness ratio
The incremental cost-effectiveness ratio of HAART
was calculated by the following formula:
Incremental cost per LY or QALY gained =
(Estimated lifetime cost of antiretroviral drugs per
patient in the HAART era − Estimated lifetime
cost of antiretroviral drugs per patient during the
pre-HAART era)/(Estimated mean lifetime sur-
vival or mean quality-adjusted survival in the
HAART era − Estimated mean lifetime survival 
or mean quality-adjusted survival during the pre-
HAART era).
E(QAS x ) x xi i i⎡
∞
⎡ ⎡= E q t S t dt
0
∫ ( ( )) ( )
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Sensitivity analysis
Due to uncertainties in the estimation of long-
term survival time after diagnosis of HIV-infected
patients in the HAART era, we conducted sen-
sitivity analysis on survival estimates to see
whether the length of survival time had a signifi-
cant effect on the incremental cost-effectiveness
ratio.
Results
HAART-associated survival improvements
A dramatic improvement in patients’ survival was
observed during the HAART era compared with
the pre-HAART era. The Kaplan–Meier survival
curves of patients presenting with AIDS (AIDS
group) during the pre-HAART era (n = 259) and
the HAART era (n = 718) are shown in Figure 1A,
and those of patients initially without AIDS-
defining illness (non-AIDS group) during the
pre-HAART era (n = 997) and the HAART era (n =
2633) are shown in Figure 1B. The estimated life-
time survival curves are shown in Figure 2. In the
AIDS group, the life expectancy (mean survival
time) after the diagnosis of HIV infection in-
creased from 1.47 ± 1.70 years (mean ± standard
error) during the pre-HAART era to 10.61 ± 3.15
years during the HAART era; in the non-AIDS
group, the corresponding increase was from
10.45 ± 2.16 years to 21.53 ± 5.72 years during
the HAART era (Table).
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Figure 1. Observed survival curves for HIV-positive patients during the pre-HAART era (April 1, 1984 to March 31,
1997) and the HAART era (May 1, 1997 to April 30, 2003): (A) AIDS group (n = 259 vs. 718); (B) non-AIDS group
(n = 997 vs. 2633).
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Figure 2. Projected lifetime survival curves for HIV-positive patients during the pre-HAART and HAART eras: (A) AIDS
group; (B) non-AIDS group.
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Estimation of QALE gained after HAART
Figure 3 shows the temporal trend in health pro-
files and health utility after the diagnosis of HIV
infection, calculated from cross-sectional data
from a total of 224 patients including 63 AIDS
patients (22 diagnosed during the pre-HAART
era) and 161 non-AIDS patients (58 diagnosed
during the pre-HAART era). The longest follow-up
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Health profile: social domain Figure 3A. Temporal trends in quality of life after the diag-
nosis of HIV infection, calculated from cross-sectional data
of 224 patients: AIDS group (n = 63). The kernel type
smoother with bandwidth 0.1 was used to estimate the
mean quality of life over time (the solid line). The health
profiles were measured by the WHOQOL-BREF instrument.
Health utility was measured by the standard gamble method.
Table. Cost and cost-effectiveness of highly active antiretroviral therapy (HAART)
HAART era Pre-HAART era
AIDS group Non-AIDS group AIDS group Non-AIDS group
Estimated mean ± SEM survival time, year 10.61 ± 3.15 21.53 ± 5.72 1.47 ± 1.70 10.45 ± 2.16
Estimated mean ± SEM QALE, QALY 7.75 ± 2.30 14.64 ± 3.89 1.07 ± 1.24 7.11 ± 1.47
Mean lifetime cost of ART per patient (NT$) 1,658,913 2,744,176 46,246 238,370
Incremental cost per LY gained (NT$) 176,441 226,156 – –
Incremental cost per QALY gained (NT$) 241,700 332,582 – –
SEM = standard error of the mean; QALE = quality-adjusted life expectancy; QALY = quality-adjusted life-year; ART = antiretroviral therapy; LY = life-year.
time after diagnosis among these 224 patients
was 12.25 years. Both the AIDS and non-AIDS
groups showed no temporal trend of decrease in
either health utility or any health profile over the
follow-up period (Figure 3). We therefore applied
a constant value for health utility in the QALE es-
timation. The QALE of AIDS patients after diag-
nosis increased from 1.07 ± 1.2 QALY to 7.75 ±
2.30 QALY, while that of non-AIDS patients in-
creased from 7.11 ± 1.47 QALY to 14.6 ± 3.89
QALY (Table).
Cost of antiretroviral therapy
In 2000 in Taiwan, the average annual NHI ex-
penditure on HAART per HIV-positive patient 
receiving HAART was NT$210,018 (US$6177 at an
exchange rate of 34.0 NT$/US$). There was no
change in the price of HAART from 2000 to 2004.
Based on the assumptions of a stable price for
HAART afterwards, and an annual discount rate
of 3%, the cumulative cost of lifetime HAART was
estimated to be NT$1,658,913 per patient in the
AIDS group, and NT$2,744,176 per patient in the
non-AIDS group. The annual cost of antiretroviral
therapy during the pre-HAART era was estimated
to be NT$35,003 per patient. The cumulative
cost of lifetime antiretroviral therapy during the
pre-HAART era was estimated to be NT$46,246
and NT$238,370 in the AIDS and non-AIDS
groups, respectively.
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Figure 3B. Temporal trends in quality of life after the diag-
nosis of HIV infection, calculated from cross-sectional data
of 224 patients: non-AIDS group (n = 161). The kernel type
smoother with bandwidth 0.1 was used to estimate the
mean quality of life over time (the solid line). The health
profiles were measured by the WHOQOL-BREF instru-
ment. Health utility was measured by the standard gamble
method.
Cost-effectiveness of HAART
Incremental cost for each LY and 
QALY gained
The incremental costs are shown in the Table. 
For the AIDS group, the cost was NT$176,441
(US$5189) per LY gained and NT$241,700
(US$7109) per QALY gained. For the non-AIDS
group, the corresponding costs were NT$226,156
(US$6652) and NT$332,582 (US$9782), 
respectively.
Sensitivity analysis
Uncertainty in estimated survival time in the
HAART era has a minimal effect on the incremen-
tal cost-effectiveness ratio. A variation within one
standard error of the mean in estimated survival
time in the HAART era resulted in a range of incre-
mental cost-effectiveness ratio from NT$159,747
(US$4698) to NT$210,691 (US$6197) per LY
gained for the AIDS group. Similarly, a variation
within one standard error of the mean in esti-
mated survival time in the HAART era resulted in
a range of incremental cost-effectiveness ratio
from NT$187,053 (US$5502) to NT$348,716
(US$10,256) per LY gained for the non-AIDS
group.
Discussion
Our analyses showed that the incremental cost-
effectiveness ratio of HAART for HIV infection
was NT$176,441–226,156 (US$5189–6652) per
LY gained and NT$241,700–332,582 (US$7109–
9782) per QALY gained, depending on the stage of
HIV diseases. Although there has been no objective
cut-off value in the interpretation of the results of
cost-effectiveness, most authorities have agreed that
the threshold for cost-effectiveness is somewhere
between US$20,000/QALY and US$100,000/
QALY, with thresholds of US$50,000–60,000/
QALY frequently proposed in other developed
countries.27–31 An incremental cost-effectiveness
ratio of NT$241,700–332,582 (US$7109–9782, at
34.0 NT$/US$) per QALY gained in Taiwan seems
well below the lower cut-off value of US$20,000/
QALY, or, is much better than those reported from
the United States (US$13,000–23,000/QALY)8 or
Canada (US$12,913–14,587/LY).12
A major determinant of the cost-effectiveness
ratio, of course, is the drug price. We found that
the unit cost of HAART per patient per year
(NT$210,018 or US$6177 in 2000) in Taiwan
was significantly lower than those anticipated
from the wholesale price in the United States
(US$2500 per patient per year for the nucleoside
analogs to US$8000 per patient per year for 
one of the protease inhibitors in 1998).7,8 It ap-
peared that Taiwan obtained a reasonable dis-
count during price negotiations. In many parts of
the world, however, concerns about access to
HAART and market competition have resulted in
mass production of less expensive generic drugs
and reduction in the prices of many brand-name
products.32–34 Generic antiretroviral drugs may
cost only one-tenth of the brand-name prod-
ucts.33 As a result, South Africa can reach an in-
cremental cost-effectiveness ratio of as low as
US$675–1622 per LY gained.13 In Taiwan, there
was no change in the price of HAART from 2000
to 2004 because the efficacy of generic drugs re-
mained uncertain during this period and brand-
name products were therefore used to ensure the
quality and effectiveness of antiretroviral agents.
If the quality of generic drugs can be demonstrated,
introduction of these less expensive products to
replace brand-name ones may significantly reduce
the financial burden of providing HAART. The cost
reduction of antiretroviral agents would likely
further improve the cost-effectiveness profile of
HAART in the future.
There are several limitations and underesti-
mations in the present assessment of the cost-
effectiveness of HAART. First, since quality of 
life data were unavailable during the pre-HAART
era, we used a conservative best-case analysis, as-
suming that the quality of life in HIV-infected
patients was the same between the pre-HAART
and HAART eras. Several studies, however, have
shown that treatment with HAART actually im-
proved the overall quality of life.35,36 Therefore,
the actual QALY gain during the HAART era might
have been better than our estimates. Second, in
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the present study, we did not consider the costs
of medical care other than HAART, the intangi-
ble cost of fear and suffering, and the indirect cost
to patients and their families. Because the med-
ical costs other than HAART included at least the
use of ventilator for pneumonia and various ex-
pensive antimicrobial agents for opportunistic
infections, which depended on the standard of
clinical care and have been rapidly evolving, it is
difficult to objectively model a longitudinal trend
in cost by analyzing available cross-sectional data.
It is also difficult to quantify the intangible cost
and indirect cost longitudinally. Since many stud-
ies consistently showed that HAART decreased the
risks of opportunistic infections and associated
hospitalization,2,4–6,37 we would anticipate an ad-
justment in a favorable direction if we consider the
cost of medical care other than HAART. In addi-
tion, HAART also provides renewed health, more
employment38 and hope for the future39 for HIV-
infected patients. Therefore, there will be a further
favorable adjustment.
From an epidemiologic viewpoint, the uni-
versal availability of HAART also greatly benefit
people who are not yet infected. HAART pro-
foundly suppresses HIV-RNA levels in blood and
other body fluids and therefore decreases the in-
fectiousness of HIV-infected patients,1,2 which
probably slowed down the spread of the HIV
epidemic in Taiwan during 1997–2002 and was
demonstrated in our previous study.1 Thus, a uni-
versal HAART policy will contribute additional
LY gain through averting new HIV cases. Although
HAART alone cannot eradicate the HIV epidemic
and must be accompanied by effective HIV-related
risk-reduction intervention,40 the ethical accept-
ability and the willingness to participate in volun-
tary screening and counseling programs actually
depend on the availability of HAART.41,42 If these
factors are also considered, the cost-effectiveness
ratio of HAART would be even better than the
current estimates.
In conclusion, our analyses show that HAART
for HIV infection is cost-effective, with an incre-
mental cost-effectiveness ratio of NT$176,441–
226,156 (US$5189–6652) per LY gained and
NT$241,700–332,582 (US$7109–9782) per QALY
gained. If we consider the cost of medical care
other than HAART, the intangible cost, the indi-
rect cost to patients and their families, the reduc-
tion of HIV transmission, and the facilitation of
HIV screening and risk reduction programs, the
cost-effectiveness ratio would be even better. We
therefore recommend that providing free access
to HAART to all HIV-infected citizens should be
continued.
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